Roffman Miller Associates Inc. PA decreased its stake in GlaxoSmithKline PLC (NYSE:GSK) by 20.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,169 shares of the pharmaceutical company’s stock after selling 1,788 shares during the period. Roffman Miller Associates Inc. PA’s holdings in GlaxoSmithKline PLC were worth $309,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Pekin Singer Strauss Asset Management IL increased its stake in GlaxoSmithKline PLC by 1.1% in the first quarter. Pekin Singer Strauss Asset Management IL now owns 5,516 shares of the pharmaceutical company’s stock valued at $233,000 after buying an additional 60 shares during the period. Court Place Advisors LLC increased its stake in GlaxoSmithKline PLC by 1.0% in the first quarter. Court Place Advisors LLC now owns 8,481 shares of the pharmaceutical company’s stock valued at $358,000 after buying an additional 84 shares during the period. Park National Corp OH increased its stake in GlaxoSmithKline PLC by 1.9% in the first quarter. Park National Corp OH now owns 6,314 shares of the pharmaceutical company’s stock valued at $266,000 after buying an additional 118 shares during the period. NEXT Financial Group Inc increased its stake in GlaxoSmithKline PLC by 0.9% in the second quarter. NEXT Financial Group Inc now owns 13,396 shares of the pharmaceutical company’s stock valued at $578,000 after buying an additional 118 shares during the period. Finally, Camelot Portfolios LLC increased its stake in GlaxoSmithKline PLC by 0.6% in the first quarter. Camelot Portfolios LLC now owns 20,786 shares of the pharmaceutical company’s stock valued at $876,000 after buying an additional 120 shares during the period. Institutional investors own 8.99% of the company’s stock.
GlaxoSmithKline PLC (NYSE GSK) traded down 0.15% during midday trading on Tuesday, hitting $38.95. The company’s stock had a trading volume of 2,217,886 shares. The stock has a 50 day moving average of $41.54 and a 200 day moving average of $41.88. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.58. The company has a market cap of $95.19 billion, a PE ratio of 37.67 and a beta of 1.03.
GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. On average, equities analysts expect that GlaxoSmithKline PLC will post $2.85 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 5.04%. The ex-dividend date is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is currently 197.00%.
GSK has been the subject of several recent research reports. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Tuesday, July 18th. ValuEngine downgraded GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $44.67.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.
